CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Inibio Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Inibio Co Ltd
506, Songnae-daero
Phone: +82 326838080p:+82 326838080 BUCHEON, 14445  South Korea Fax: +82 326838089f:+82 326838089
Business Summary
Inibio Co Ltd is a Korea-based company engaged in the research and development (R&D) of pharmaceuticals and medical devices. The Company is engaged in the operation of projects including cosmeceuticals, medical devices, biopharmaceuticals, natural products, and cosmetics.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201912/31/2019Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Chief Executive Officer, Director Cheong SeKim
Co-Chief Executive Officer, Director Gi SeLee

General Information
Outstanding Shares: 61,357 (As of 12/31/2019)
Fax Number: +82 326838089


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023